People: Omeros Corp (OMER.OQ)

OMER.OQ on NASDAQ Stock Exchange Global Market

12.13USD
2:28pm EDT
Price Change (% chg)

$-0.05 (-0.41%)
Prev Close
$12.18
Open
$12.08
Day's High
$12.40
Day's Low
$11.97
Volume
28,609
Avg. Vol
98,177
52-wk High
$18.78
52-wk Low
$6.92

Search Stocks

Summary

Name Age Since Current Position

Gregory Demopulos

55 2013 Chairman of the Board, President, Chief Executive Officer

Michael Jacobsen

55 2013 Chief Accounting Officer, Vice President - Finance, Treasurer

Marcia Kelbon

54 2007 Vice President - Patent, General Counsel, Secretary

Thomas Cable

74 1995 Lead Independent Director

Peter Demopulos

60 1995 Director

Ray Aspiri

77 2007 Independent Director

Arnold Hanish

66 2012 Independent Director

Leroy Hood

75 2001 Independent Director

Biographies

Name Description

Gregory Demopulos

Dr. Gregory A. Demopulos, M.D., is Chairman of the Board, President, Chief Executive Officer of Omeros Corp. He is one of founders and has served as president, chief executive officer and chairman of the board of directors since June 1994 and, in an interim capacity, as chief financial officer and treasurer since January 2009. He also served as chief medical officer from June 1994 to March 2010. Prior to founding Omeros, Dr. Demopulos completed his residency in orthopedic surgery at Stanford University and his fellowship training at Duke University. Dr. Demopulos currently serves on the board of directors of Onconome, Inc., a privately held company developing biomarkers for early cancer detection. Dr. Demopulos received his M.D. from the Stanford University School of Medicine and his B.S. from Stanford University.

Michael Jacobsen

Mr. Michael A. Jacobsen has been appointed as Chief Accounting Officer, Vice President - Finance, Treasurer of Omeros Corporation. Mr. Jacobsen, 55, joined Omeros on September 3, 2013. Prior to joining Omeros, Mr. Jacobsen served as Vice President of Finance of Sarepta Therapeutics, Inc., a publicly traded biotechnology company, from September 2011 to May 2013 and as its Chief Accounting Officer from September 2011 to December 2012. At Sarepta, Mr. Jacobsen’s responsibilities included finance and accounting, purchasing, facilities and information technology. From April 2007 to August 2011, Mr. Jacobsen was Vice President and Chief Accounting Officer at ZymoGenetics, Inc., a publicly traded biotechnology company acquired by Bristol-Myers Squibb in October 2010. Prior to his service with ZymoGenetics, Mr. Jacobsen held various roles from October 2001 to April 2007 at ICOS Corporation, a publicly traded biotechnology company acquired by Eli Lilly in January 2007, including Senior Director of Finance and Corporate Controller. From April 1995 to October 2001, Mr. Jacobsen held Vice President of Finance or Chief Financial Officer roles at three companies in the software, computer hardware and internet retailing industries, two of which were publicly traded. Mr. Jacobsen is a certified public accountant and received his bachelor’s degree in accounting from Idaho State University. .

Marcia Kelbon

Ms. Marcia S. Kelbon, J.D., serves as Vice President - Patent, General Counsel, Secretary of Omeros Corp. Prior to that, Ms. Kelbon was a partner with the firm of Christensen O’Connor Johnson & Kindness, PLLC, where she specialized in U.S. and international intellectual property procurement, management, licensing and enforcement issues. Ms. Kelbon received her J.D. and her M.S. in chemical engineering from the University of Washington and her B.S. from The Pennsylvania State University.

Thomas Cable

Mr. Thomas J. Cable serves as Lead Independent Director of Omeros Corp. He has served on board of directors since January 1995. He has also served on audit committee since January 1995 and on compensation committee since December 2007. In addition, Mr. Cable has served as chairman of nominating and governance committee since September 2009. Mr. Cable is the chairman of the board of the Washington Research Foundation, a technology transfer and early stage venture capital organization affiliated with the University of Washington, which he co-founded in 1980. Mr. Cable also founded Cable & Howse Ventures, a venture capital firm, and Cable, Howse & Ragen, an investment banking firm. In addition, Mr. Cable co-founded Montgomery Securities, an investment banking firm acquired by Bank of America. A former U.S. Navy submarine officer, Mr. Cable received his M.B.A. from the Stanford Graduate School of Business and his B.A. from Harvard University.

Peter Demopulos

Dr. Peter A. Demopulos, M.D., FACC, FSCAI, serves as Director of Omeros Corp., since January 1995. Dr. Demopulos is a practicing board-certified general and interventional cardiologist at Seattle Cardiology, part of the Swedish Heart & Vascular Institute. He has been a member of Seattle Cardiology from 2005 to the present, also serving as its Medical Director from 2005 to 2010. Dr. Demopulos is also a clinical assistant professor of cardiology at the University of Washington School of Medicine, a position that he has held since 1989. He participates as an investigator in clinical trials evaluating interventional cardiology devices and drug therapies at Seattle Cardiovascular Research and Swedish Cardiovascular Research. Dr. Demopulos received his M.D. from the Stanford University School of Medicine and his B.S. from Stanford University.

Ray Aspiri

Mr. Ray Aspiri serves as an Independent Director of Omeros Corp. He has served on board of directors since January 1995 and previously served as treasurer from January 1999 to September 2007. Mr. Aspiri has also served as chairman of compensation committee since January 1995 and as a member of nominating and governance and audit committees since September 2009 and July 2011, respectively. From his founding of the company in 1997 until its sale in December 2012, Mr. Aspiri served as the chairman of the board of Tempress Technologies, Inc., a privately held research and development company that specialized in high-pressure fluid dynamics for the oil and gas industry. From 1980 to 1997, Mr. Aspiri served as the chairman of the board and chief executive officer of Tempress, Inc., a privately held company specializing in products for the truck, marine and sporting goods industries.

Arnold Hanish

Mr. Arnold C. Hanish serves as an Independent Director of Omeros Corp. From 1994 until his retirement in December 2012, Mr. Hanish served as vice president, chief accounting officer, at Eli Lilly and Company. Prior to his appointment as chief accounting officer, he held a number of senior financial positions at Eli Lilly. Before Eli Lilly, Mr. Hanish held various positions at Arthur Young & Company (currently Ernst & Young) for nearly 14 years. Mr. Hanish was a member of the Standing Advisory Group of the Public Company Accounting Oversight Board through December 31, 2012. In addition, from 2007 to 2010, he served as the chairperson of Financial Executives International’s Committee on Corporate Reporting. Mr. Hanish earned his B.A. in accounting from the University of Cincinnati.

Leroy Hood

Dr. Leroy E. Hood, M.D., Ph.D., serves as an Independent Director of Omeros Corp., since March 2001. He also has served on nominating and governance committee since September 2009 and on compensation committee since July 2011. Dr. Hood previously served as a member of audit committee from September 2009 to December 2009 and from June 2012 to September 2012. Dr. Hood is the president of the Institute for Systems Biology, a non-profit research institute dedicated to the study and application of systems biology, which he co-founded in 2000. Previously, Dr. Hood was founder and chairman of the Department of Molecular Biotechnology at the University of Washington School of Medicine. Dr. Hood also co-founded Amgen, Inc., Applied Biosystems, Inc., Darwin Molecular Technologies, Inc., Rosetta Inpharmatics, Inc. and SyStemix, Inc. Dr. Hood is a member of the National Academy of Sciences, the American Philosophical Society, the American Association of Arts and Sciences, the Institute of Medicine and the National Academy of Engineering. Dr. Hood received his Ph.D. and B.S. from the California Institute of Technology and his M.D. from The John Hopkins School of Medicine.

Basic Compensation

Name Fiscal Year Total

Gregory Demopulos

3,250,980

Michael Jacobsen

787,233

Marcia Kelbon

1,045,140

Thomas Cable

--

Peter Demopulos

--

Ray Aspiri

--

Arnold Hanish

--

Leroy Hood

--
As Of 30 Dec 2013

Options Compensation

Name Options Value

Gregory Demopulos

10,000 103,100

Michael Jacobsen

0 0

Marcia Kelbon

15,103 64,672

Thomas Cable

0 0

Peter Demopulos

0 0

Ray Aspiri

0 0

Arnold Hanish

0 0

Leroy Hood

0 0
Search Stocks